Zenjiro Sampei

Yokohama, 2448602, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function.

Long lasting complement neutralisation by RAY121, an engineered anti-C1s antibody with C1q displacement function.

Journal: EBioMedicine

Published: April 24, 2025

Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment.

Beyond Recycling Antibodies: Crovalimab's Molecular Design Enables Four-Weekly Subcutaneous Injections for PNH Treatment.

Journal: International journal of molecular sciences

Published: October 02, 2024

Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion.

Rapid in vitro assessment of the immunogenicity potential of engineered antibody therapeutics through detection of CD4+ T cell interleukin-2 secretion.

Journal: mAbs

Published: September 08, 2023

Monte Carlo Thompson sampling-guided design for antibody engineering.

Monte Carlo Thompson sampling-guided design for antibody engineering.

Journal: mAbs

Published: August 22, 2023

Efficient production of bispecific antibody by FAST-IgTM and its application to NXT007 for the treatment of hemophilia A.

Efficient production of bispecific antibody by FAST-IgTM and its application to NXT007 for the treatment of hemophilia A.

Journal: mAbs

Published: June 20, 2023

A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.

A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.

Journal: Journal of thrombosis and haemostasis : JTH

Published: June 14, 2023

Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement.

Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement.

Journal: Antibodies (Basel, Switzerland)

Published: March 10, 2023

Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering.

Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering.

Journal: mAbs

Published: April 28, 2022

Correction to: A Novel Total Drug Assay for Quantification of Anti-C5 Therapeutic Monoclonal Antibody in the Presence of Abundant Target.

Correction to: A Novel Total Drug Assay for Quantification of Anti-C5 Therapeutic Monoclonal Antibody in the Presence of Abundant Target.

Journal: The AAPS journal

Published: January 20, 2021

A Novel Total Drug Assay for Quantification of Anti-C5 Therapeutic Monoclonal Antibody in the Presence of Abundant Target.

A Novel Total Drug Assay for Quantification of Anti-C5 Therapeutic Monoclonal Antibody in the Presence of Abundant Target.

Journal: The AAPS journal

Published: April 21, 2020

In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity.

In vitro human helper T-cell assay to screen antibody drug candidates for immunogenicity.

Journal: Journal of immunotoxicology

Published: June 11, 2019

Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.

Antibody engineering to generate SKY59, a long-acting anti-C5 recycling antibody.

Journal: PloS one

Published: September 10, 2018

Showing 1-12 of 17

Last Updated: 09/26/2026